These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10978263)

  • 1. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I; Renucci JF; Grimaux M; Morange PE; Gouvernet J; Gourmelin Y; Alessi MC
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2156-61. PubMed ID: 10978263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Marx PF; Mosnier LO; Meijers JC
    Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
    van Tilburg NH; Rosendaal FR; Bertina RM
    Blood; 2000 May; 95(9):2855-9. PubMed ID: 10779431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
    Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
    Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
    Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A; Oliver A; Borrell M; Mateo J; Belvis R; Martí-Fábregas J; Ortín R; Tirado I; Souto JC; Fontcuberta J
    Stroke; 2003 Oct; 34(10):2387-91. PubMed ID: 12947154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
    Aubert H; Frère C; Aillaud MF; Morange PE; Juhan-Vague I; Alessi MC
    J Thromb Haemost; 2003 Apr; 1(4):791-7. PubMed ID: 12871417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I; Morange PE; Aubert H; Henry M; Aillaud MF; Alessi MC; Samnegård A; Hawe E; Yudkin J; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):867-73. PubMed ID: 12006404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M; Osman N; Hefnawy S; El Hawy MA
    Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ; Leebeek FW; Tanck MW; Wouter Jukema J; Kluft C; de Maat MP
    Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia.
    Meijers JC; Oudijk EJ; Mosnier LO; Bos R; Bouma BN; Nieuwenhuis HK; Fijnheer R
    Br J Haematol; 2000 Mar; 108(3):518-23. PubMed ID: 10759708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
    Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
    Lisman T; Leebeek FW; Mosnier LO; Bouma BN; Meijers JC; Janssen HL; Nieuwenhuis HK; De Groot PG
    Gastroenterology; 2001 Jul; 121(1):131-9. PubMed ID: 11438502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J; Schulman S; Eelde A; Blombäck M
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.